Colin J. Meyer
Net Worth
Last updated:
What is Colin J. Meyer net worth?
The estimated net worth of Dr. Colin J. Meyer is at least $37,880,947 as of 16 Aug 2023. He has earned $29,822,797 from insider trading and has received compensation worth at least $8,058,150 in Reata Pharmaceuticals, Inc..
What is the salary of Colin J. Meyer?
Dr. Colin J. Meyer salary is $895,350 per year as Executive Vice President and Chief R&D Officer in Reata Pharmaceuticals, Inc..
How old is Colin J. Meyer?
Dr. Colin J. Meyer is 46 years old, born in 1979.
What stocks does Colin J. Meyer currently own?
As insider, Dr. Colin J. Meyer owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Reata Pharmaceuticals, Inc. (RETA) | Executive Vice President and Chief R&D Officer | 81,633 | $0 | $0 |
What does Reata Pharmaceuticals, Inc. do?
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Colin J. Meyer insider trading
Reata Pharmaceuticals, Inc.
Dr. Colin J. Meyer has made 15 insider trades between 2016-2023, according to the Form 4 filled with the SEC. Most recently he sold 596 units of RETA stock worth $100,569 on 16 Aug 2023.
The largest trade he's ever made was exercising 40,000 units of RETA stock on 15 Jun 2021. As of 16 Aug 2023 he still owns at least 81,633 units of RETA stock.
Reata Pharmaceuticals key executives
Reata Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Colin J. Meyer (46) Executive Vice President and Chief R&D Officer
- Mr. J. Warren Huff (71) Chairman, Chief Executive Officer & Pres
- Mr. Manmeet Singh Soni (47) Chief Operating Officer, Chief Financial Officer & Executive Vice President
- Mr. Michael D. Wortley (77) Executive Vice President & Chief Legal Officer
- Ms. Dawn Carter Bir (54) Executive Vice President & Chief Commercial Officer